Skip to main content

RGNT · Regentis Biomaterials Ltd.

Track RGNT — free
$1.89 -0.07 (-3.57%) At close · Sep 11
Market Cap
$13.28M
Shares
7.02M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.89 Open$2.02 Day$1.89–2.02 Available close range$1.28–9.40 Avg vol 30d50K Short int13K · 0.2% float · 1.0d Short vol32% DataDec 2025–Sep 2026

The closing range uses available history since Dec 4, 2025; less than a full year is stored.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
Trailing 12 months
Net income (TTM)
Trailing 12 months
Revenue growth YoY
Year over year
Operating margin
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
-79.5%
Year over year · fewer shares
Price change (1Y)
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −16%
below
RSI (14) 41
neutral
MACD trend Positive
52-week position 8%
near low
Momentum
relative strength
Very Weak
1-month return −1%
trailing
6-month return −40%
trailing
YTD return −72%
this year
Relative strength −58%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+100% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.19% of float · ▲ +64.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — 13F breadth
Squeeze score 37
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 632%
annualized · 1-yr
Max drawdown −83%
past year
ATR 9.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−16% Bearish
RSI (14)
41 Neutral
MACD trend
Positive Bullish
52-week position
8% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+100% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.19% of float · ▲ +64.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — 13F breadth
Price context
position in its available closing range
Range low $1 Now $2 · 8% Range high $9
vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RGNT
Regentis Biomaterials Ltd.
this stock
$13.28M -72.0% 0.2%
ISRG
Intuitive Surgical Inc
$130.41B -34.8% +20.5% 42.4 2.2%
BDX
Becton Dickinson & Co
$48.31B +8.2% 3.9%
MDLN
Medline Inc.
$42.77B -22.5% +11.5% 3.0%
ALC
Alcon Inc
$31.95B -16.2% +10.5% 3.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
6
% held
12.0%
Net QoQ
+293.9K sh
Top holder
Rosalind Advisors, Inc.
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
13.5K
Days to cover
1.0d
Change
+5.3K sh
View
Short Volume
Short vol %
32%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
3.3K
Value
$6.1K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
56.4%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-13.6M
EPS diluted
$-24.16
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 11, 2026
This year
19
View
Exempt Offerings
Offering
$6.5M
Filed
Jun 25, 2026
View

Performance

5D 20D 120D MTD YTD
RGNT -4.1% -0.5% -40.1% -7.4% -72.0%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -2.9% +1.2% -57.9% -7.0% -84.0%
Key facts CIK 1912966 CUSIP M8211G108 13F (30d) 4 filings 4 filers Visit website Investor relations